by Bruce Sylvester – Chronic obstructive pulmonary disease (COPD) patients involved in moderate to vigorous physical activity are at a lower risk of hospital readmission within 30 days… read more.
by Bruce Sylvester – Researchers from the Joints on Glucosamine study (JOG) report that oral glucosamine supplementation does not reduce knee cartilage deterioration in osteoarthritis or improve knee… read more.
by Bruce Sylvester – Using ordinary instrumentation plus a computer during nocturnal insulin delivery, scientists have found a method to predict and prevent dangerously low overnight blood sugars… read more.
Emerging uses of FDA approved drugs – by Bruce Sylvester – Over half of depressed subjects in a newly reported study who were injected with onabotulinumtoxinA (OBA/Botox) achieved… read more.
by Bruce Sylvester – Emerging uses of FDA approved drugs – Eplerenone, a drug used to reduce the risk of death in patients with heart failure, shows significant… read more.
by Bruce Sylvester – Emerging uses of FDA approved drugs – Immunosuppresant drugs used to prevent organ rejection after transplantation could become used in fighting persistent HIV infection,… read more.
by Bruce Sylvester – Emerging uses of FDA-approved drugs – Treatment with acetazolamide plus a low-sodium weight-reduction diet for patients diagnosed with idiopathic intracranial hypertension (IIH)mand mild vision… read more.
by Bruce Sylvester – A 15% drop in dietary salt use from 2003-2011 in England and a 40% drop in deaths from heart disease and stroke during the… read more.
by Bruce Sylvester – Researchers report that administering blood pressure lowering drugs to patients in the first 48 hours after a stroke does not lower the risk of… read more.
by Bruce Sylvester – Researchers report that simvastatin could become a treatment option for the secondary progressive, or chronic, stage of multiple sclerosis (MS).
by Bruce Sylvester – On March 29, 2014, investigators presented results from three separate evolocumab trials at the American College of Cardiology annual meeting/ACC2014. Evolocumab is a human… read more.
by Bruce Sylvester – Post non-cardiac surgery treatment with low-dose clonidine increased rates of clinically important hypotension and non-fatal cardiac arrest, researchers from the POISE-2 trial have reported.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
